Short-chain fatty acids ameliorate experimental anti-glomerular basement membrane disease

Copyright © 2024 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 259(2024) vom: 01. Feb., Seite 109903
1. Verfasser: Liu, Jing (VerfasserIn)
Weitere Verfasser: Gu, Qiu-Hua, Cui, Zhao, Zhao, Ming-Hui, Jia, Xiao-Yu
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Anti-GBM disease Immunity Inflammation Short-chain fatty acids sodium propionate DK6Y9P42IN Butyric Acid 107-92-6 mehr... Sodium Acetate 4550K0SC9B Propionates
LEADER 01000caa a22002652c 4500
001 NLM36708760X
003 DE-627
005 20250305162850.0
007 cr uuu---uuuuu
008 240114s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2024.109903  |2 doi 
028 5 2 |a pubmed25n1223.xml 
035 |a (DE-627)NLM36708760X 
035 |a (NLM)38218211 
035 |a (PII)S1521-6616(24)00014-7 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Liu, Jing  |e verfasserin  |4 aut 
245 1 0 |a Short-chain fatty acids ameliorate experimental anti-glomerular basement membrane disease 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 29.01.2024 
500 |a Date Revised 10.04.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2024 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: Short-chain fatty acids (SCFAs), as the link between gut microbiota and the immune system, had been reported to be protective in many autoimmune diseases by the modulation of T cell differentiation. The pathogenic role of autoreactive Th1 and Th17 cells and the protective role of Treg cells in the pathogenesis of anti-GBM disease have been fully demonstrated. Thus, the present study aimed to investigate the therapeutic effects of SCFAs in a rat model of anti-GBM disease 
520 |a MATERIALS AND METHODS: Experimental anti-GBM disease was constructed by immunizing Wistar Kyoto rats with a nephrogenic T cell epitope α3127-148, and intervened by sodium acetate, sodium propionate, or sodium butyrate, 150 mM in the drinking water from day 0 to 42. Kidney injury was accessed by the biochemical analyzer, immunofluorescence, and immunohistochemistry. Antibody response was detected by ELISA. T cell clustering and proliferation were detected by flow cytometry. Human kidney 2 (HK2) cells were stimulated in vitro and cytokines were assessed by quantitative real-time PCR 
520 |a RESULTS: Treatment with sodium acetate, sodium propionate, or sodium butyrate ameliorated the severity of kidney impairment in rats with anti-GBM glomerulonephritis. In the sodium butyrate-treated rats, the urinary protein, serum creatinine, and blood urea nitrogen levels were significantly lower; the percentage of crescent formation in glomeruli was significantly reduced; and the kidneys showed reduced IgG deposition, complement activation, T cell, and macrophage infiltration as well as the level of circulating antibodies against anti-α3(IV)NC1. The treatment of sodium butyrate reduced the α3127-148-specific T cell activation and increased the Treg cells differentiation and the intestinal beneficial bacteria flora. It also alleviated the damage of HK2 cells treated with inflammatory factors and complement 
520 |a CONCLUSION: Treatment with SCFAs, especially butyrate, alleviated anti-GBM nephritis in rat model, indicating its potential therapeutic effects in clinical usage 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Anti-GBM disease 
650 4 |a Immunity 
650 4 |a Inflammation 
650 4 |a Short-chain fatty acids 
650 7 |a sodium propionate  |2 NLM 
650 7 |a DK6Y9P42IN  |2 NLM 
650 7 |a Butyric Acid  |2 NLM 
650 7 |a 107-92-6  |2 NLM 
650 7 |a Sodium Acetate  |2 NLM 
650 7 |a 4550K0SC9B  |2 NLM 
650 7 |a Propionates  |2 NLM 
700 1 |a Gu, Qiu-Hua  |e verfasserin  |4 aut 
700 1 |a Cui, Zhao  |e verfasserin  |4 aut 
700 1 |a Zhao, Ming-Hui  |e verfasserin  |4 aut 
700 1 |a Jia, Xiao-Yu  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 259(2024) vom: 01. Feb., Seite 109903  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:259  |g year:2024  |g day:01  |g month:02  |g pages:109903 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2024.109903  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 259  |j 2024  |b 01  |c 02  |h 109903